Brought to you by 
Affymax brings in $60mm with Series D round
20 Jul 2005
Executive Summary
Affymax (peptide drugs for cancer and immune diseases) has raised $60mm through a Series D financing to new and returning buyers. New investors JAFCO (co-lead), Bessemer Venture Partners, Merlin BioMed, and Diamond Capital participated along with existing backers Bear Stearns Health Innoventures (co-lead), Apax Partners, MPM Capital, and Sprout Group.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Affymax brings in $60mm with Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice